- Conditions
- Pancreatic Cancer
- Interventions
- NP137
- Drug
- Lead sponsor
- Aram Hezel
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Rochester, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 1,136
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neoplastic Cells, Circulating, Pancreatic Cancer, Biological Markers
- Interventions
- No intervention/exposures
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
- Interventions
- AFNT-211
- Drug
- Lead sponsor
- Affini-T Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 10
- States / cities
- Los Angeles, California • New Haven, Connecticut • New York, New York + 5 more
- Conditions
- Solid Tumors, Multiple Myeloma, Non-Hodgkins Lymphoma, Pancreatic Neuroendocrine Tumors, PNET, NHL
- Interventions
- DCR-MYC
- Drug
- Lead sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 6
- States / cities
- Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more
- Conditions
- Cancer Pain, Visceral Pain, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract, Small Intestine Cancer, Pancreas Cancer, Liver Cancer, Colon Cancer, Biliary Tract Cancer, Stomach Cancer, Rectum Cancer, Peritoneal Cancer, Gastrointestinal Cancer Metastatic, Gastrointestinal Cancers - Anus, Gastrointestinal Cancers - Stomach, Gastrointestinal Cancers - Colorectal, Gastrointestinal Cancers - Small Intestine, Small Intestine Cancer Stage III, Small Intestine Cancer Stage IV, Small Intestine Cancer, Recurrent, Pancreas Cancer, Stage III, Pancreas Cancer, Stage IV, Pancreas Cancer, Metastatic, Pancreas Cancer, Recurrent, Liver Cancer Stage IIIa, Liver Cancer Stage IIIb, Liver Cancer Stage IIIc, Liver Cancer Stage IV, Colon Cancer Stage III, Colon Cancer Stage IV, Stomach Cancer Stage III, Stomach Cancer Stage IV, Stomach Cancer Recurrent, Rectum Cancer, Recurrent, Gastrointestinal Cancers - Liver, Anal Cancer, Anal Cancer Stage III, Anal Cancer Stage IV, Anal Cancer Recurrent, Anal Cancer Metastatic, Anal Cancer, Stage IIIA, Anal Cancer, Stage IIIB, Appendix Cancer, Ampullary Cancer, Bile Duct Cancer, Bile Duct Cancer Stage III, Bile Duct Cancer Stage IV, Bile Duct Cancer Stage IVA, Bile Duct Cancer Stage IVB, Bile Duct Cancer Recurrent, Carcinoid Tumor, Carcinoid Tumor of Pancreas, Carcinoid Tumor of Large Intestine, Carcinoid Tumor of GI System, Carcinoid Tumor of Colon, Carcinoid Tumor of Liver, Carcinoid Tumor of Cecum, Carcinoid Tumor of Ileum, Carcinoid Tumor of Rectum, Carcinoid Tumor of the Small Bowel, Carcinoid Tumor of the Stomach, Large Intestine Cancer, Esophagus Cancer, Esophagus Cancer, Stage III, Esophagus Cancer, Stage IV, Esophagus Cancer, Recurrent, Gallbladder Cancer, Gallbladder Cancer Stage III, Gallbladder Cancer Stage IV, Gastric (Stomach) Cancer, Neuroendocrine Tumor, Peritoneum Cancer, Rectal Cancer, Esophagus Cancer, Stage I, Esophagus Cancer, Stage II, Gallbladder Cancer Stage I, Gallbladder Cancer Stage II, Bile Duct Cancer Stage I, Bile Duct Cancer Stage II
- Interventions
- PICO G2 4k
- Device
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- Gemcitabine, Taxotere, Xeloda, Cisplatin, Irinotecan
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 76 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- Safety Laboratories, AE Assessment, Physical Exam, Concomitant Medication Review, Tumor Imaging, nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate, FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate, Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate
- Diagnostic Test · Other · Drug
- Lead sponsor
- HonorHealth Research Institute
- Other
- Eligibility
- 18 Years to 105 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Pancreatic Cancer, Metastatic Pancreatic Cancer
- Interventions
- CPI 613 in Combination With Gemcitabine and Nab-paclitaxel
- Drug
- Lead sponsor
- Atlantic Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Morristown, New Jersey • Summit, New Jersey
- Conditions
- Advanced Malignant Solid Neoplasm, Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
- Interventions
- BET Bromodomain Inhibitor ZEN-3694, Computed Tomography, Core Biopsy, Entinostat
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Gainesville, Florida • Oklahoma City, Oklahoma
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer), Metastatic Non-Small Lung Cell Cancer, Metastatic Colorectal Cancer (CRC), KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12S, KRAS G12V, Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Lung Carcinoma, Solid Tumor, Adult
- Interventions
- BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab, mFOLFOX6, BBO-10203, mFOLFIRINOX, Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 665 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 12 more
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Gemcitabine, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Veliparib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Harvey, Illinois • Ann Arbor, Michigan + 6 more
- Conditions
- Pancreatic Cancer
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic
- Interventions
- FOLFIRNINOX, Losartan, 9-ING-41
- Drug
- Lead sponsor
- Colin D. Weekes, M.D., PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Boston, Massachusetts • Charlestown, Massachusetts + 1 more
- Conditions
- Pancreatic Cancer
- Interventions
- HyperAcute(R)-Pancreatic Cancer Vaccine
- Biological
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Pancreatic Cancer
- Interventions
- tumor infiltrating lymphocyte therapy, gemcitabine hydrochloride
- Biological · Drug
- Lead sponsor
- Meyer Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Gastric and Pancreatic Cancer
- Interventions
- washings for experimental marker testing
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Melanoma, Pancreatic Ductal Adenocarcinoma
- Interventions
- YH003, Toripalimab, Nab-paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Eucure (Beijing) Biopharma Co., Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Interventions
- RMC-6236
- Drug
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 754 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 21
- States / cities
- Orange, California • Santa Monica, California • Tampa, Florida + 16 more
- Conditions
- Pancreatic Head Mass
- Interventions
- Transgastric diagnostic endoscopic peritoneoscopy
- Procedure
- Lead sponsor
- Jeffrey Hazey
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms
- Interventions
- Gemcitabine Delivered by Transarterial Microperfusion
- Combination Product
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Pancreatic Cancer
- Interventions
- tipifarnib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- RX-3117
- Drug
- Lead sponsor
- Processa Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Weeki Wachee, Florida • Joliet, Illinois + 7 more
- Conditions
- Pancreatic Cancer, Neoplasm Metastasis, Adenocarcinoma
- Interventions
- talabostat mesylate tablets, gemcitabine
- Drug
- Lead sponsor
- Point Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 28
- States / cities
- Florence, Alabama • Muscle Shoals, Alabama • Hartford, Connecticut + 20 more
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome
- Interventions
- AMG 706, octreotide
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 112
- States / cities
- Berwyn, Illinois • Chicago, Illinois • Joliet, Illinois + 78 more